Page 3 - Ensuring Timely Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Keith A Zullow and Jenny J Zhang examine upcoming US pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma.

The Big Molecule Watch is monitoring pending legislation in Congress that relates to biosimilars and biologics. In this post, we check in on the status of two currently pending bills...

POLITICO Get the Prescription Pulse newsletter Email Sign Up By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Presented by Gilead Sciences, Inc. With Emily Martin and Dan Goldberg On Tap — Michigan lawmakers want Biden to send extra vaccine doses to the hard-hit state. — The Congressional Budget Office takes a deep dive on pharmaceutical R&D.

340B: 266 House Legislators Want Fines for Drug Companies Two hundred sixty-six members of the House of Representatives have told the Department of Health and Human Services that HHS should fine drug companies that deny 340B discounts to hospitals for drugs dispensed by contract pharmacies and to make drug companies pay hospitals back for discounts that were withheld. The letter says it’s the long-held position of the Health Resources and Services Administration that drug companies must provide 340B discounts to hospitals and clinics that qualify, regardless of whether hospitals dispense th...